Exchange: NASDAQ·Updated 07:53 PM EDT

BCRX News

News
all
press releases
BCRX Stock Heads For Fifth Straight Day In The Red – RBC Capital Says BioCryst Faces A ‘Challenging Near-Term Outlook’
RBC Capital said it expects revenue tailwinds for BioCryst’s Orladeyo drug after Pharvaris posted strong Phase 3 data for HAE therapy.
Stocktwits
More News
BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease
Pharvaris said on Tuesday its once-daily experimental pill cut monthly swelling attacks by 83% versus a dummy treatment in a late-stage study of hereditary angioedema patients.
Stocktwits
Is BioCryst Pharmaceuticals (BCRX) Stock Outpacing Its Medical Peers This Year?
Here is how BioCryst Pharmaceuticals (BCRX) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
Zacks
BioCryst’s Orladeyo Built The Cash Pile, CEO Gayer Wants To Buy The Next Asset
CEO Gayer told CNBC in an interview that the company is now profitable and plans to use that cash to invest in other rare-disease medicines.
Stocktwits
Wall Street Analysts Think BioCryst (BCRX) Could Surge 108.21%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 108.2% in BioCryst (BCRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks
Wall Street Analysts See a 98.74% Upside in BioCryst (BCRX): Can the Stock Really Move This High?
The consensus price target hints at a 98.7% upside potential for BioCryst (BCRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks
Implied Volatility Surging for BioCryst Pharmaceuticals Stock Options
Investors need to pay close attention to BCRX stock based on the movements in the options market lately.
Zacks
BioCryst Bets On Rare Genetic Disorder Therapy Expansion Amid Q2 Earnings Beat – Retail Piles On Buyout Speculation
BioCryst raised its full-year 2026 total revenue outlook to $690 million to $715 million, up from its previous estimates of $635 million to $660 million.
Stocktwits
BioCryst Pharmaceuticals (BCRX) Tops Q2 Earnings and Revenue Estimates
BioCryst (BCRX) delivered earnings and revenue surprises of +114.29% and +18.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Biocryst Pharmaceuticals Inc Q2 Profit Climbs
(RTTNews) - Biocryst Pharmaceuticals Inc (BCRX) released earnings for its second quarter that Increased, from the same period last year...
Nasdaq News: Markets

Advertisement|Remove ads.